.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EF02_Ribociclib.Ribociclib

Information

Ribociclib is an orally active, selective cyclin-dependent kinase (CDK) 4/6 inhibitor used for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. It is commonly used in combination with endocrine therapies, and is approved for use in multiple regions as of 2024.

Pharmacokinetics

Pharmacokinetic parameters based on data from adult patients with advanced breast cancer, both sexes, oral administration under fasting or fed state.

References

1. Damoiseaux, D, et al., & Dorlo, TPC (2022). Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs. Pharmaceuticals (Basel, Switzerland) 15(7) –. DOI:10.3390/ph15070860 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35890158

2. Samant, TS, et al., & Elmeliegy, M (2018). Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations. Clinical pharmacology and therapeutics 104(2) 374–383. DOI:10.1002/cpt.940 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29134635

3. Roncato, R, et al., & Cecchin, E (2022). An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer. Frontiers in pharmacology 13 897951–None. DOI:10.3389/fphar.2022.897951 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35942220

Revisions

• 06/2025 initial generated model